Puma Biotechnology, Inc. (NASDAQ:PBYI)
Industry: Biotechnology

OFF LIST - 1019 consecutive market days: OFF LIST as of 05/17/2012 Through 11/14/2016

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Current Quote*
Last: $3.425
Change: 0.000
Book: $Unk
Volume: 245,022

As Of: 07/11 16:12 ET
*Quotes delayed by 20min.

Graphs for PBYI


3 Month Graph


6 Month Graph


1 Year Graph